Citigroup Inc. assumed coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a report released on Thursday, The Fly reports. The brokerage issued a positive rating and a $19.00 price objective on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut Seres Therapeutics from a hold rating to a sell rating in a report on Wednesday. Seaport Global Securities reiterated a buy rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen and Company reiterated a buy rating on shares of Seres Therapeutics in a report on Monday, October 2nd. ValuEngine cut Seres Therapeutics from a hold rating to a sell rating in a report on Thursday, September 21st. Finally, Cantor Fitzgerald reiterated a buy rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $18.00.

Seres Therapeutics (NASDAQ MCRB) traded up 1.10% during trading on Thursday, hitting $10.99. The company had a trading volume of 361,110 shares. The stock has a 50-day moving average of $14.07 and a 200-day moving average of $14.07. The stock’s market capitalization is $445.23 million. Seres Therapeutics has a one year low of $8.86 and a one year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.00 million. During the same quarter in the previous year, the business posted ($0.70) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts anticipate that Seres Therapeutics will post ($2.55) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/15/citigroup-inc-begins-coverage-on-seres-therapeutics-inc-mcrb.html.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock worth $17,911,000 after acquiring an additional 19,363 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Seres Therapeutics by 21.5% during the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after acquiring an additional 135,276 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Seres Therapeutics by 15.9% during the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after acquiring an additional 50,860 shares during the period. State Street Corp boosted its holdings in shares of Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after acquiring an additional 34,393 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock worth $2,664,000 after acquiring an additional 32,875 shares during the period. Institutional investors own 74.76% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

The Fly

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.